Joe Rogan's Influence Gets Trump to Sign Psychedelic Executive Order Worth Millions

In a surprising turn of events that highlights the unconventional power dynamics of the Trump administration, podcaster Joe Rogan played a pivotal role in convincing President Trump to sign an executive order accelerating research on psychedelic drugs for therapeutic use.

From Podcast to Policy

The executive order, signed Saturday in the Oval Office with Rogan present, focuses on fast-tracking research into psychedelics like ibogaine as treatments for depression, PTSD, and other mental health conditions. Trump explicitly credited Rogan as a major inspiration behind the initiative, particularly regarding ibogaine—a psychedelic substance banned in the United States but used internationally for PTSD treatment.

Rogan has been championing ibogaine for years on his massively popular podcast. Just a year ago, he told listeners that "Ibogaine, in particular, has helped a lot of people. It gives you, like, a review of your life, apparently." Two weeks before the signing, Rogan interviewed W Bryan Hubbard, CEO of Americans for Ibogaine, who also attended the Oval Office ceremony.

According to Rogan, the policy change came about through direct communication with Trump. "Sounds great, do you want FDA approval?" Trump reportedly responded to Rogan's texts about the issue. "It was literally that quick," Rogan told reporters.

Billionaire Backing and Market Speculation

While the executive order frames psychedelic research as a public health initiative, significant financial interests are at play. The move has created potential windfalls for early-stage investors who have been positioning themselves in what many see as the next cannabis-style market boom.

Billionaire tech investor Peter Thiel emerges as a major potential beneficiary. He has spent nearly a decade investing heavily in psychedelic pharmaceutical companies, including Compass Pathways, a British firm working to commercialize psilocybin (the active ingredient in magic mushrooms) for therapeutic use. Thiel has also backed AtaiBeckley, a German company developing hallucinogenic treatments.

The market responded immediately to Trump's announcement. Stocks of both Compass Pathways and AtaiBeckley spiked Thursday on news that Trump would likely approve ibogaine research over the weekend.

State-Level Investments and Conservative Backing

Texas stands to benefit significantly from the federal push, having announced $50 million in state funding for ibogaine clinical trials in late March. The timing suggests coordination between state and federal initiatives that could accelerate research timelines.

Conservative financial backing also plays a role. The Mercer Family Foundation, a major conservative grantmaker that supported Trump's election, has donated over $1 million toward psychedelics-related PTSD treatment for combat veterans. This conservative support helps explain how psychedelic research gained traction in Trump's administration despite traditional Republican skepticism toward drug policy reform.

Strained Relationship Continues

The ibogaine executive order comes despite recent tensions between Trump and Rogan. The podcaster has been critical of Trump's military actions in Iran, prompting Trump to label Rogan a "liberal"—a characterization Rogan would likely reject. However, their collaboration on psychedelic policy suggests their relationship remains influential despite public disagreements.

Trump's Personal Interest

In a characteristic moment during Saturday's signing ceremony, Trump jokingly asked for some ibogaine himself. "Can I have some, please?" he said. "I'll do whatever it takes...I don't have time to be depressed. If you stay busy enough, maybe that's what works too, that's what I do."

The comment, while likely made in jest, underscores Trump's personal engagement with the policy—a factor that often determines which initiatives receive presidential attention in his administration.

Looking Forward

The executive order represents a significant shift in federal drug policy, potentially opening doors for broader psychedelic research and commercialization. With major investors positioned to profit and states ready to conduct trials, the initiative could reshape both mental health treatment and create substantial new markets.

Whether this represents genuine healthcare innovation or primarily serves wealthy investors' interests remains to be seen. What's clear is that Joe Rogan's influence extends far beyond podcasting, directly shaping federal policy in ways that could benefit millions of Americans—and make some very rich people even richer.